文献速递前列腺癌

低深度全基因组测序循环肿瘤DNA揭示前列腺癌治疗中的行为

Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA.
PubMed 文献 · Eur Urol · 2021-06-05

本研究基于FIRSTANA和PROSELICA两项三期试验的血浆样本,对188例mCRPC患者进行低深度全基因组测序,评估循环肿瘤DNA的预后与应答价值。肿瘤分数可独立预测总生存(HR 1.75,95%CI 1.08-2.85;p=0.024),且优于现有生物标志物(C指数0.722 vs 0.709;p=0.021);纵向变化与药物应答相关,大规模转位与既往阿比特龙/恩扎卢胺治疗相关。

要点

  • 血浆肿瘤分数是mCRPC总生存的独立预后因素,且较现有标志物提供附加价值。
  • 治疗过程中肿瘤分数的纵向变化与药物应答相关。
  • 大规模转位富集提示基因组不稳定,与既往阿比特龙/恩扎卢胺治疗相关。

核心结论

  • 血浆ctDNA低深度全基因组测序可反映mCRPC行为,提供具有临床相关性的预后和应答数据。

研究设计与样本

  • 研究纳入两项前瞻性三期试验(FIRSTANA和PROSELICA)中同意亚研究的mCRPC患者,共188例、540份血浆样本,四个时间点(筛查、第1周期、第4周期和研究结束)进行lpWGS。
  • FIRSTANA中化疗初治患者随机接受多西他赛75 mg/m2或卡巴他赛20或25 mg/m2;PROSELICA中多西他赛经治患者随机接受卡巴他赛20或25 mg/m2。

主要发现

  • 血浆肿瘤分数在单变量和分层多变量分析中均与总生存相关(HR 1.75,95%CI 1.08-2.85;p=0.024)。
  • 肿瘤分数较现有生物标志物提供附加预后价值(C指数0.722 vs 0.709;p=0.021)。
  • 肿瘤分数的纵向变化与药物应答相关。
  • PROSELICA样本中大规模转位富集(p=0.029),提示基因组不稳定,且与既往阿比特龙和恩扎卢胺治疗相关,但与紫杉类或放疗无关。
  • 较高的大规模转位与RB1/RNASEH2B缺失相关,独立于BRCA2缺失。

关键数值与推荐

  • 肿瘤分数预后HR为1.75(95%CI 1.08-2.85;p=0.024)。
  • 肿瘤分数附加预后价值C指数0.722 vs 0.709(p=0.021)。
  • PROSELICA样本大规模转位富集p=0.029。

临床怎么用

  • 血浆lpWGS检测ctDNA肿瘤分数可辅助mCRPC预后评估,并动态监测治疗应答。
  • 大规模转位等基因组指标可提示既往特定治疗(如阿比特龙/恩扎卢胺)相关的基因组不稳定。

局限性

  • 研究为两项试验的探索性亚组分析,样本量有限。
  • ctDNA分数较现有标志物的附加预后价值需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Better blood tests to elucidate the behaviour of metastatic castration-resistant prostate cancer (mCRPC) are urgently needed to drive therapeutic decisions. Plasma cell-free DNA (cfDNA) comprises normal and circulating tumour DNA (ctDNA). Low-pass whole-genome sequencing (lpWGS) of ctDNA can provide information on mCRPC behaviour. OBJECTIVE: To validate and clinically qualify plasma lpWGS for mCRPC. DESIGN, SETTING, AND PARTICIPANTS: Plasma lpWGS data were obtained for mCRPC patients consenting to optional substudies of two prospective phase 3 trials (FIRSTANA and PROSELICA). In FIRSTANA, chemotherapy-naïve patients were randomised to treatment with docetaxel (75 mg/m2) or cabazitaxel (20 or 25 mg/m2). In PROSELICA, patients previously treated with docetaxel were randomised to 20 or 25 mg/m2 cabazitaxel. lpWGS data were generated from 540 samples from 188 mCRPC patients acquired at four different time points (screening, cycle 1, cycle 4, and end of study). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: lpWGS data for ctDNA were evaluated for prognostic, response, and tumour genomic measures. Associations with response and survival data were determined for tumour fraction. Genomic biomarkers including large-scale transition (LST) scores were explored in the context of prior treatments. RESULTS AND LIMITATIONS: Plasma tumour fraction was prognostic for overall survival in univariable and stratified multivariable analyses (hazard ratio 1.75, 95% confidence interval 1.08-2.85; p = 0.024) and offered added value compared to existing biomarkers (C index 0.722 vs 0.709; p = 0.021). Longitudinal changes were associated with drug response. PROSELICA samples were enriched for LSTs (p = 0.029) indicating genomic instability, and this enrichment was associated with prior abiraterone and enzalutamide treatment but not taxane or radiation therapy. Higher LSTs were correlated with losses of RB1/RNASEH2B, independent of BRCA2 loss. CONCLUSIONS: Plasma lpWGS of ctDNA describes CRPC behaviour, providing prognostic and response data of clinical relevance. The added prognostic value of the ctDNA fraction over established biomarkers should be studied further. PATIENT SUMMARY: We studied tumour DNA in blood samples from patients with prostate cancer. We found that levels of tumour DNA in blood were indicative of disease prognosis, and that changes after treatment could be detected. We also observed a "genetic scar" in the results that was associated with certain previous treatments. This test allows an assessment of tumour activity that can complement existing tests, offer insights into drug response, and detect clinically relevant genetic changes.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Sumanasuriya S, Seed G, Parr H, et al. Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA. Eur Urol. 2021. PMID: 34103179. doi:10.1016/j.eururo.2021.05.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。